Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).Karim Fizazi, Stéphane Culine, F. Rolland et al.|Journal of Clinical Oncology|2011Cited by 9
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patientsCécile Vicier, Karim Fizazi, Laurence Faivre et al.|Annals of Oncology|2016Cited by 0